Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

222 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of Small Tumor Size on Prognosis in T3N1 Colon Cancer.
Tamai K, Tei M, Tsujimura N, Nishida K, Mori S, Yoshikawa Y, Nomura M, Hamakawa T, Takiuchi D, Tsujie M, Akamaru Y. Tamai K, et al. Among authors: tei m. World J Surg. 2025 Jan 11. doi: 10.1002/wjs.12480. Online ahead of print. World J Surg. 2025. PMID: 39798098
The Efficacy of FOLFIRI Plus Ramucirumab in Recurrent Colorectal Cancer Refractory to Adjuvant Chemotherapy with Oxaliplatin/Fluoropyrimidine-Including Biomarker Analyses.
Sugimoto N, Noura S, Kato T, Yoshioka S, Hata T, Naito A, Tei M, Tamagawa H, Komori T, Ide Y, Fukuzaki T, Danno K, Sawada G, Kagawa Y, Shimokawa T, Miyoshi N, Ogino T, Uemura M, Yamamoto H, Murata K, Doki Y, Eguchi H. Sugimoto N, et al. Among authors: tei m. Cancers (Basel). 2024 Dec 30;17(1):91. doi: 10.3390/cancers17010091. Cancers (Basel). 2024. PMID: 39796720 Free PMC article.
Modified FOLFOXIRI plus cetuximab versus bevacizumab in RAS wild-type metastatic colorectal cancer: a randomized phase II DEEPER trial.
Shiozawa M, Sunakawa Y, Watanabe T, Ota H, Yasui H, Yabuno T, Tei M, Kochi M, Manaka D, Ohori H, Yamaguchi T, Sagawa T, Kotaka M, Kubota Y, Sekikawa T, Nakamura M, Takeuchi M, Ichikawa W, Fujii M, Tsuji A. Shiozawa M, et al. Among authors: tei m. Nat Commun. 2024 Nov 25;15(1):10217. doi: 10.1038/s41467-024-54460-2. Nat Commun. 2024. PMID: 39587053 Free PMC article. Clinical Trial.
Influence of the rotation of the diverting loop ileostomy in rectal cancer surgery on small-bowel obstruction: A multicenter prospective study conducted by the Clinical Study Group of Osaka University, Colorectal Group.
Miyo M, Uemura M, Ozato Y, Nishimura J, Nakata K, Suzuki Y, Kagawa Y, Hata T, Munakata K, Tei M, Sawada G, Yoshioka S, Takahashi Y, Oba K, Hata T, Ogino T, Miyoshi N, Yamamoto H, Murata K, Doki Y, Eguchi H; Clinical Study Group of Osaka University, Colorectal Group (CSGO-CG). Miyo M, et al. Among authors: tei m. Surgery. 2025 Feb;178:108874. doi: 10.1016/j.surg.2024.09.032. Epub 2024 Nov 7. Surgery. 2025. PMID: 39516112
Phase II trial evaluating the long-term efficacy and peripheral sensory neuropathy of capecitabine plus oxaliplatin (XELOX) as adjuvant therapy in Japanese patients with operated stage III colon cancer.
Hata T, Uemura M, Danno K, Yoshioka S, Matsuda C, Kagawa Y, Shingai T, Suzuki Y, Tei M, Tanida T, Komori T, Okamura S, Ota H, Takemoto H, Ogino T, Miyoshi N, Yamamoto H, Murata K, Doki Y, Eguchi H. Hata T, et al. Among authors: tei m. Sci Rep. 2024 Nov 2;14(1):26434. doi: 10.1038/s41598-024-73222-0. Sci Rep. 2024. PMID: 39488510 Free PMC article. Clinical Trial.
222 results